Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Roberts in-licenses another GI drug from Lilly

Dec. 10, 1996

Successful phase III results reported for British Biotech PAF antagonist

Dec. 9, 1996

Cytel to implement new development strategy for HBV vaccine

Dec. 6, 1996

Phase IIa trial on Isis antiinflammatory antisense compound completed

Dec. 5, 1996

Axcan-Schwarz joint venture to market URSO

Dec. 2, 1996

Chugai discloses erythromycins for gastrointestinal disorders

Nov. 27, 1996

OraVax and Pasteur-Merieux Connaught license H. pylori genome sequence

Nov. 26, 1996

Lilly claims 5-HT7 antagonist for GI indications

Nov. 26, 1996

New market introduction for proton pump inhibitor

Nov. 26, 1996

Neose reports promising phase I results for novel antiulcer drug

Nov. 25, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...